Vineet Laboratories Limited (VINEETLAB) - Total Liabilities
Based on the latest financial reports, Vineet Laboratories Limited (VINEETLAB) has total liabilities worth Rs764.24 Million INR (≈ $8.26 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore VINEETLAB shareholders equity momentum to track the company's year-over-year net asset growth rate.
Vineet Laboratories Limited - Total Liabilities Trend (2017–2025)
This chart illustrates how Vineet Laboratories Limited's total liabilities have evolved over time, based on quarterly financial data. See cash generation quality of Vineet Laboratories Limited to measure how efficiently the company converts operating cash flow to free cash.
Vineet Laboratories Limited Competitors by Total Liabilities
The table below lists competitors of Vineet Laboratories Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
DarkIris Inc. Class A Ordinary Shares
NASDAQ:DKI
|
USA | $1.66 Million |
|
Khaitan (India) Limited
NSE:KHAITANLTD
|
India | Rs444.93 Million |
|
Intanwijaya Internasional Tbk
JK:INCI
|
Indonesia | Rp73.38 Billion |
|
Puri Global Sukses Tbk Pt
JK:PURI
|
Indonesia | Rp428.63 Billion |
|
Touchwood Entertainment Limited
NSE:TOUCHWOOD
|
India | Rs133.18 Million |
|
Mason Graphite Inc.
V:LLG
|
Canada | CA$149.56K |
|
PYRAMID AG NA KONV.
XETRA:M3B0
|
Germany | €32.68 Million |
|
PATRYS Ltd
AU:PAB
|
Australia | AU$1.01 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down Vineet Laboratories Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see VINEETLAB stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 5.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.84 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vineet Laboratories Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vineet Laboratories Limited (2017–2025)
The table below shows the annual total liabilities of Vineet Laboratories Limited from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | Rs798.92 Million ≈ $8.64 Million |
-2.75% |
| 2024-03-31 | Rs821.48 Million ≈ $8.88 Million |
-0.02% |
| 2023-03-31 | Rs821.66 Million ≈ $8.89 Million |
-18.17% |
| 2022-03-31 | Rs1.00 Billion ≈ $10.86 Million |
+22.27% |
| 2021-03-31 | Rs821.26 Million ≈ $8.88 Million |
+20531525.00% |
| 2020-03-31 | Rs4.00K ≈ $43.26 |
-94.65% |
| 2019-03-31 | Rs74.78K ≈ $808.72 |
-35.80% |
| 2018-03-31 | Rs116.48K ≈ $1.26K |
+1064.80% |
| 2017-03-31 | Rs10.00K ≈ $108.15 |
-- |
About Vineet Laboratories Limited
Vineet Laboratories Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and fine chemicals primarily in India. The company offers intermediates of Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine, and other API intermediates. It also provides fine chemicals and reagents, such as isopropyl… Read more